A recent study highlights how microfluidic platforms are revolutionizing single-cell sequencing (SCS), enabling breakthroughs in cancer diagnostics and precision therapy. These technologies allow high-throughput, cost-effective isolation and analysis of individual tumor cells—critical for understanding tumor heterogeneity, drug resistance, and immune interactions.
Advanced microfluidic systems—like droplet-based, microwell, and digital microfluidics (DMF)—now automate single-cell capture, barcoding, and sequencing, minimizing reagent use and improving clinical scalability.
These compact lab-on-chip tools are transforming oncology by supporting liquid biopsies, multi-omic profiling, and real-time mutation tracking, helping tailor treatment plans at the single-cell level.
